InfuSystem Holdings Inc (INFU)
AMEXHealth CareMedical - DevicesSnapshot 2026-09-09
$12.20+2.61%
Close 2026-09-09 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-09-09
Intact: The reason to own it still holds.
InfuSystem keeps growing sales about 6% a year to $33.7 million in 2026. Profit margins stay in the mid to low 20% range. The company is buying back $20 million of stock, showing confidence. Earnings beats have been consistent recently.
Sales growth could slow below 6% if demand weakens. Profit margins might shrink from mid-20% levels. Stock buybacks may not offset valuation pressure. Legal or regulatory issues could hurt results.
The stock price is about 33% below our valuation level. Analysts expect roughly 6% revenue growth. The market reflects moderate growth and margin stability but not strong upside.
Breaks if: Adjusted EBITDA margin falls below low 20% range in FY26
Breaks if: Revenue falls below $33.7 million in FY26
Stock buyback program is not executed or is materially delayed
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on steady growth. The current thesis state is intact, supported by strong recent financial performance and management's guidance.
The market appears to have a neutral valuation, with expectations slightly above current performance levels. INFU is viewed as cheap compared to its peers, indicating that some positive future developments may already be priced in.
Management is on track to maintain adjusted EBITDA margins in the mid to low 20% range. Revenue growth guidance for 2026 is reaffirmed, suggesting a stable trajectory despite some near-term risks.
Key factors include potential cuts to guidance, which could negatively impact sentiment. Additionally, broader economic conditions, such as job market performance, will influence investor perception. Positive earnings from sector leaders could also provide momentum.
The most important moves since the prior daily snapshot.
Valuation rose by 12.7 points (from 35.6 to 48.3).
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Overall, INFU's performance and management execution suggest a stable outlook for the next 1 to 3 years. Not investment advice.